VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2012

May 11, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2012-05-09

Reporting Person: ULLIAN ELAINE (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-05-09	Common Stock	M	20000	$28.40	Acquired	25265	Direct
2012-05-09	Common Stock	S	20000	$60.58	Disposed	5265	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-05-09	Stock Option	$28.40	M	20000	Disposed	2018-05-31	Common Stock (20000)	Direct

Footnotes

F1: Open market sales reported on this line occurred at a weighted average price of $60.58 (range $60.50 to $60.71).

F2: Ms. Ullian undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3: Fully vested.